Strategic partnerships INmune Bio is actively expanding collaborations, notably with Anthony Nolan and CGT Catapult, signaling a willingness to co-develop and scale advanced therapies. This openness to partnerships creates avenues for joint ventures, licensing, and manufacturing collaborations that sales teams can leverage to cross-sell complementary services and accelerate market access.

Diversified pipelines The company pursues multiple modalities including INKmune for NK cell priming and XPro1595 with preclinical data in HER2-positive breast cancer, plus stem cell therapy initiatives like CORDStrom for RDEB. This breadth offers multiple entry points for collaborations with biotech, pharma, and contract development/manufacturing organizations seeking to co-develop or sponsor studies across oncology and rare diseases.

Clinical-stage focus As a clinical-stage immuno-oncology company with trials and preclinical assets, INmune Bio presents opportunities for clinical development partnerships, sponsored research arrangements, and late-stage co-development discussions as assets progress toward safety and efficacy milestones that attract potential partners and investors.

Public engagements Active participation in industry events (AACR, CTAD, Clinical Trials on Alzheimer's Disease) and media coverage indicate ongoing visibility and validation opportunities. Sales teams can leverage these moments to engage with researchers, clinicians, and potential partners who attend these events and seek collaboration or access to INmune’s platforms and data.

Manufacturing readiness Recent collaboration with Cell and Gene Therapy Catapult to develop commercial-scale manufacturing capabilities suggests a readiness to discuss scalable production and supply chain services. This creates a sales angle for contract manufacturing, process development, and technology transfer partnerships to support broader commercialization.